Brivaracetam
As of the edition of 20 October 2026, Brivaracetam is a small molecule: marketed, first approved in 2016 (EU); acts on SV2A; US protection ended in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Briviact
- First approved
- 13 January 2016 (EU)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- SUN FARMACĂUTICA DO BRASIL LTDA; 5 holders in all
- Registered trials
- 52, 5 stopped early
- Disease areas
- Nervous system; Inherited and neonatal; Injuries; Cancer; Mental health
US protection
US protection ended in 2026.
The last listed US drug-substance patent ended in 2026. The application that gives this date is held by UCB.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product8 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 8 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Brivaracetam.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SV2A | Synaptic vesicle glycoprotein 2A | Q7L0J3 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 4 | 0 | 0 |
| Phase 1 | 11 | 8 | 0 | 1 |
| Phase 2 | 10 | 8 | 1 | 1 |
| Phase 3 | 26 | 21 | 2 | 3 |
| All trials | 52 |